Increasing adoption of microfluidic technology to produce miniaturized microfluidic chips used in molecular diagnosis and analysis, is expected to boost growth of the microfluidic market. For instance, in March 2016, 908 Devices Inc. launched, ZipChip, a microfluidic device that provides high quality separation possibilities to mass spectroscopy enabling fast analysis for a broader range of biomolecules.

Advancement in microfluidic technology such as sample droplet production technique, microfluidic sensors, lab-on-a-chip, microfluidic enabled microscope, and microfluidic valve controller helps to further augment growth of the microfluidic market. Moreover technology advancement in microfluidic saves the time, eliminate the need of expensive laboratory robots and reduce the risk of sample loss and contamination. For instance, in February 2017, researchers at the Stanford University School of Medicine have developed a relatively cheap and reusable diagnostic lab-on-a-chip for medical diagnostic application, which is expected to enhance the diagnostic capabilities and would be a highly feasible option in emerging economies.

Request for a sample of this research report @ https://www.coherentmarketinsights.com/insight/request-sample/1086

Controlled drug delivery system deliver the drug at target sites, in desired quantity, and on time thus, enhancing drug efficiency, bioavailability, and pharmacokinetics while maintaining minimum side effects. Microfluidic-based devices are adopted significantly for micro and nano-scale drug delivery, maintaining the physiochemical characteristics of drug, at the target location. For instance, researchers at the Massachusetts Eye and Ear Infirmary, Harvard Medical School and Charles Stark Draper Laboratory in Massachusetts developed microfluidic based automated micropump device for direct delivery of drugs into the perilymph fluid within the cochlea- an auditory portion of the inner ear.

Major factors influencing growth of the microfluidic market is rising demand for point-of-care (POC) testing and advancements in microfluidic technology to reduce cost of sample analysis and enabling higher efficiency. Moreover, increasing demand for home healthcare to address growing prevalence of diabetes is supporting to growth of the microfluidic market. For instance, in 2017 researchers at the Ewha Womens University developed an endocrine system on chip, based on microfluidic perfused 3D cell-culture chip which detect the drugs for the treatment of diabetes by measuring insulin release over time.

Request for Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1086

According to the statistics published by International Diabetes Federation (IDF), the global prevalence of diabetes is around 424.9 million in 2017, which is expected to increase to 628.6 million in 2045. In addition, increasing innovation in microfluidics technology is further expected to bolster growth of the market. Researchers at the Brigham Young University, in April 2017, developed first 3D-print viable microfluidic device which has size less than 100 micrometers and employed to use in molecular biology, proteomics and cell biology diagnostic technologies.

Key players in the microfluidic market are emphasizing on introducing innovative solutions based on microfluidic technology for a wide range of applications. For instance, in November 2017, Dolomite Bio introduced Nadia- a single-cell platform for single-cell RNA sequencing. Nadia is droplet microfluidic based instrument that can generate 6,000 single-cell libraries per sample in just 15 minutes. It also aids researchers to run multiple samples parallelly. Dolomite Bio combines the microfluidic technology with automated temperature control and cell/bead agitation in single instrument that delivers highly precise and reliable results.

Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1086

Some of the major players operating in the microfluidic market are Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Fluidigm Corporation, Danaher Corporation, PerkinElmer Inc., Siemens Healthcare GmbH, and Micronit Microfluidic BV

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]